Company intelligence / Profile preview
Fortis Therapeutics
La Jolla, California, United Statesfortistx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Fortis developed FOR46, a fully human antibody-drug conjugate targeting CD46. In Phase 1 trials for mCRPC and multiple myeloma, FOR46 showed anti-tumor activity in heavily pre-treated patients. The company completed dose escalation and expansion cohorts in both indications. As of May 2023, the sole clinical asset was licensed to FibroGen for further development; Fortis has no active pipeline post-deal. Recent results from the Phase 1 monotherapy study were published in March 2025 and support continued development by FibroGen.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
FibroGen – exclusive licensee of lead ADC program FG‑3246/FOR46 as of May 2023University of California San Francisco – source of foundational technology/license originator
Beyond the preview
Go deeper on Fortis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fortis Therapeutics.